INTRODUCTION
============

Bisphosphonates are a new class of agents that have been increasingly recommended for use in patients with osteoporosis, Paget\'s disease of bone, hypercalcemia of malignancy, osteolytic bone metastases, and osteolytic lesions of multiple myeloma ([Figure 1](#f01){ref-type="table"})^[@r07],[@r19]^. Despite the benefits related to use of these medications, osteonecrosis of the jaws is a significant complication in a subset of patients receiving these drugs in particular with intravenous administration. Based on a growing number of case reports and institutional reviews, bisphosphonate therapy may cause exposed and necrotic bone that is isolated to the jaw^[@r33],[@r35]^. This complication could present after simple dentoalveolar surgery. The phenomenon of bisphosphonate-related osteonecrosis of jaws (BRONJ) was recognized a few years after their approval for use^[@r01]^. Reports first appeared in 2003, alerting the dental and medical communities of this complication^[@r28],[@r37],[@r38],[@r43]^. Since brought to light in 2003^[@r23],[@r47]^, well over 400 reports have been published concerning BRONJ. Despite this large volume of work, there are few data yet many hypotheses concerning the underlying pathophysiology. The physiologic effects of bisphosphonates on bone cells, osteoblasts, osteoclasts, and osteocytes, have recently been comprehensively reviewed^[@r39],[@r40],[@r41]^.

###### 

Bisphosphonate preparations currently available in the United States (Abbreviation: Intravenous - IV, \*Relative to etidronate)

                **Primary Indication**   **Dose**                        **Route**   **Relative Potency\***
  ------------- ------------------------ ------------------------------- ----------- ------------------------
  Etidronate    Paget\'s disease         300-750 mg daily for 6 months   Oral        1
  Tiludronate   Paget\'s disease         400 mg daily for 3 months       Oral        50
  Alendronate   Osteoporosis             10 mg/day                       Oral        1,000
                                         70 mg/week                      Oral         
  Risedronate   Osteoporosis             5 mg/day                        Oral        1,000
                                         35 mg/week                      Oral         
  Ibandronate   Osteoporosis             2.5 mg/day                      Oral        1,000
                                         150 mg/months                   Oral         
                                         3 mg every 3 months             IV           
  Pamidronate   Bone metastases          90 mg/3 weeks                   IV          1,000-5,000
  Zoledronate   Bone metastases          4 mg/3 weeks                    IV          10,000 +
                Osteoporosis             5 mg/year                       IV          

Osteoclasts represent the main cellular target of bisphosphonates^[@r46]^. Specifically, bisphosphonates repress osteoclast-mediated bone remodeling, through disruption of intracellular pathways. As remodeling is a vital role process in tissue renewal and bone healing, bisphosphonate-induced remodeling suppression causes relevant effects on various tissue-level properties^[@r05],[@r07],[@r27],[@r42]^.

The effects of bisphosphonates on osteocytes are less clear and more controversial. There is a high awareness on both direct and indirect effects, most of which are centered around the viability and integrity of these cells and their environment^[@r03],[@r31],[@r32]^.

Although systemic bone formation is reduced in the presence of bisphosphonates, this is primarily an indirect consequence of remodeling suppression and the coupling between resorption and formation. At the level of the individual basic multicellular unit, osteoblast activity appears unaffected^[@r09],[@r13]^. Reports from small animal models suggest that bisphosphonates may suppress osteoblastic bone formation directly on those surfaces undergoing bone formation without prior resorption (i.e., formation modeling)^[@r21]^, although large animal models do not show a similar suppressive effect on periosteal surfaces^[@r04],[@r26]^.

In addition, this evidence shows that osteoclasts and/or osteocytes are the main cells of interest for BRONJ pathogenesis. The basic premise of this hypothesis is that the jaw has a high remodeling rate and bisphosphonates suppress remodeling. There is no debate about the latter because this is the principal mechanism of action of bisphosphonates^[@r34],[@r40],[@r41]^. It is also clear that remodeling, specifically within the intracortical envelope, is considerably higher in the jaw compared with other skeletal sites. The BRONJ hypothesis thus follows the idea that because remodeling is high in the jaw, and bisphosphonates suppress remodeling, this likely plays a role in the pathophysiology of BRONJ^[@r03],[@r24]^.

Current information on the prevalence and incidence of BRONJ (and much rarer non-bisphosphonate-associated events) is poor. These data are hampered by inconsistent definitions, as well as incomplete reporting. Unfortunately, with current information sources, it is not possible to determine the prevalence or incidence rates^[@r16]^.

Strategies for the treatment of patients with, or at risk of, BRONJ were defined in the American Association of Oral and Maxillofacial Surgeons (AAOMS) Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws (Position Paper) and approved by the Board of Trustees in September 2006^[@r01]^. The Position Paper was developed by a task force appointed by the Board and composed of clinicians with extensive experience in treating these patients and basic science researchers. The knowledge base and experience in addressing BRONJ has expanded, necessitating modifications and refinements to the original Position Paper. The task force was then called together again in August 2008 to review the 2006 recommendations, appraise the current published data, and revise the Position Paper and recommendations, where indicated. This update contains revisions to the diagnosis and staging and management strategies and highlights the status of basic science research^[@r35],[@r36],[@r38]^. The purpose of this updated Position Paper is to provide ([Figure 2](#f02){ref-type="table"}): 1. Perspectives on the risk of developing BRONJ and the risks and benefits of bisphosphonates to facilitate medical decision-making of both the treating physician and the patient; 2. Guidance to clinicians regarding the differential diagnosis of BRONJ in patients with a history of treatment with intravenous (IV) or oral bisphosphonates; 3. Guidance to clinicians on possible BRONJ prevention measures and treatment of patients with BRONJ according to the presenting stage of the disease.

###### 

Staging and treatment strategies. \[Ruggiero, et al.^[@r37]^ (2009)\]

  **BRONJ Stage\***   **Clinical description**                                                                                                                                                                                                                                                                                                                                                                                                                    **Treatment Strategies †‡§**
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  At risk category    No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates                                                                                                                                                                                                                                                                                                                                          No treatment indicated. Patient education.
  Stage 0             No clinical evidence of necrotic bone, but nonspecific clinical findings and symptoms                                                                                                                                                                                                                                                                                                                                                       Systemic management, including use of pain medication and antibiotics.
  Stage 1             Exposed and necrotic bone in asymptomatic patients without evidence of infection                                                                                                                                                                                                                                                                                                                                                            Antibacterial mouth rinse. Clinical follow-up on quarterly basis. Patient education and review of indications for continued bisphosphonate therapy.
  Stage 2             Exposed and necrotic bone associated with infectin as evidenced by pain and erythema in region of exposed bone with or without purulent drainage                                                                                                                                                                                                                                                                                            Symptomatic treatment with oral antibiotics. Oral antibacterial mouth rinse. Pain control. Superficial debridement to relieve soft tissue irritation.
  Stage 3             Exposed and necrotic bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone (inferior border and ramus in the mandible, maxillary sinus and zygoma in the maxilla), resulting in pathologic fracture, extraoral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible or the sinus floor   Antibacterial mouth rinse. Antibiotic therapy and pain control. Surgical debridement/resection for longer term palliation of infection and pain.

Abbreviations: bisphosphonate-related osteonecrosis of the jaw - BRONJ; intravenous - IV

\*Exposed bone in maxillofacial region without resolution within 8-12 weeks in persons treated with bisphosphonate who have not undergone radiotherapy to jaws

†Regardless of disease stage, mobile segments of bone sequestrum should be removed without exposing uninvolved bone; extraction of symptomatic teeth within exposed, necrotic bone should be considered because it is unlikely that extraction will exacerbate established necrotic process

‡Discontinuation of IV bisphosphonates has shown no short-term benefit. However, if systemic conditions permit, long-term discontinuation might be beneficial in stabilizing established sites of BRONJ, reducing risk of new site development, and reducing clinical symptoms. Risks and benefits of continuing bisphosphonate therapy should be made only by treating oncologist in consultation with oral and maxillofacial surgeon and patient

§Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in clinical disease. Discontinuation of oral bisphosphonates for 6-12 months may result in either spontaneous sequestration or resolution after debridement surgery. If systemic conditions permit, modification or cessation of oral bisphosphonate therapy should be done in consultation with treating physician and patient

The aim of this systematic review was to assess the role of the microsurgical reconstruction of the jaws in patents affected by bisphosphonate-related osteonecrosis ([Figure 3](#f03){ref-type="fig"}), highlighting the clinical effectiveness at short- and long-term using the vascularized fibula free flap, and evaluating biological complications after an observation period of at least 12 months in the cases of BRONJ at the 3^rd^ stage (as *per* Position Paper of American Association of Oral and Maxillofacial Surgeons -AAOMS).

![Lateral view of the right leg. Note the proximity of the common peroneal nerve to the proximal osteotomy, according to Anthony and Foster^[@r06]^ (1996)](jaos-19-04-0293-g01){#f03}

MATERIAL AND METHODS
====================

Search strategy and inclusion criteria
--------------------------------------

A systematic review of the English literature was conducted for selected articles published from January 1976 to June 2009.

Searching was performed using an full-text electronic journal database (PubMed). The following key word combinations were applied: jaw osteonecrosis, osteonecrosis bisphosphonate, bisphosphonate-related osteonecrosis, microsurgical reconstruction of the jaws, vascularized fibula flap. Manual searches of the bibliographies of all full-text articles and related reviews, selected from the electronic search, were also performed. Furthermore, manual searching was conducted in the following journals for the considered period: American Journal Medicine, Bone, British Journal of Oral and Maxillofacial Surgery, Clinical Oral Implants Related Research, Journal of Periodontology, Journal of Oral and Maxillofacial Surgery, Journal of Oral Pathology and Medicine, Journal of Prosthetic Dentistry, Oral Disease, Oral Oncology, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, Quintessence International and The Laryngoscope.

From this extensive search, it was obvious that there were no randomized controlled clinical trials (RCTs) available, prospective or retrospective studies. In the absence of RCTs, prospective or retrospective studies, this systematic review was based on clinical cases (case series, case report):

\- that had a mean follow-up time of 12 months or more;

\- obtained from publications within English dental literature;

\- where patients included had been examined clinically at follow-up visits.

Selection of studies
--------------------

Titles and abstracts of the searches were initially screened by two independent reviewers for possible inclusion in the review. The full text of all relevant studies was then obtained for independent assessment by the reviewers. Any disagreement was resolved by discussion. [Figure 4](#f04){ref-type="fig"} describes the identification process of the 5 studies which were selected from an initial yield of 947 titles. Data were extracted using a data extraction form. Disagreement regarding data extraction was resolved by consensus, after discussions ([Figure 1](#f01){ref-type="table"}).

![Search strategy](jaos-19-04-0293-g02){#f04}

Excluded studies
----------------

Six out of 11 full-text articles examined were excluded from the final analysis for different reasons: the mean observation period was \<12 months, the type of reconstructions was not performed with vascularized fibula flap and/or the osteonecrosis was an osteoradionecrosis.

Data extraction
---------------

Information on the surgical reconstructions and on biological complications was retrieved from the 5 included studies. Biological complications during the surgery, after the surgery and in the follow-up period were highlighted.

RESULTS
=======

A total of 22 patients were observed and treated in 5 different studies where 13 patients received a vascularized osteocutaneous fibula free flap reconstruction (59.09%) and 9 received only a vascularized fibula free flap reconstruction (40.90%) ([Figures 5](#f05){ref-type="table"} and [6](#f06){ref-type="table"}). All flaps survived completely and the postoperative course was uneventful with cumulative survival rate (CSR) of 100% ([Figure 6](#f06){ref-type="table"}). Exceptions were represented by 6 cases (27.27%): four patients (18.18%) had postoperative wound complications. The most common complication was fistula which in one case required a pectoralis myogenous flap for wound closure; in another case (4.54%), the rupture of a miniplate was observed but it did not require any surgical exploration in a third case (4.54%), a small hematoma formed in the anterior portion of the neck incision after approximately 2 weeks from the operation ([Figure 7](#f07){ref-type="table"}). Two patients died of cancer-related disease 8 weeks and 16 month after surgery, with no signs of recurrent BRONJ. BRONJ-related facial pain and halitosis stopped completely after the operation in all patients. The donor leg healed without complications in all cases. Stable oral lining and solid bone union were achieved in all patients. In all studies no complications were reported to the vascularized fibula free flap with 100% of success rate and recurrence of the osteonecrosis were noted only in two cases (9.09%) ([Figure 7](#f07){ref-type="table"}).

###### 

Studies retrieved from the review of the literature: analysis of medical history, type of therapy used and mandible necrosis involved

  **Reference**                  **Number** **of patients**   **Age of patients**   **Medical History**      **Pharmacological therapy used by the patients**   **Mandible necrosis involvement**
  ------------------------------ ---------------------------- --------------------- ------------------------ -------------------------------------------------- -----------------------------------
  Engroff and Kim^[@r12]^ 2007   2                            56.5 years (mean)     2 Breast cancer          1 Pz. IV Zoledronate;                              Partially
  1 Pz. OS pamidronate                                                                                                                                          
  Ferrari, et al.^[@r15]^ 2008   1                            66 years old          1 Multiple myeloma       1 Pz. IV pamidronate and later Zoledronate         Totally
  Mucke, et al.^[@r28]^ 2009     1                            60 years old          1 Multiple myeloma       1 Pz. IV Zoledronate                               Partially
  Nocini, et al.29 2009          7                            61 years (mean)       5 Pz. Breast cancer; 1   5 Pz. IV pamidronate and later Zoledronate;        2 Totally,
  Pz. Prostate cancer;           2 Pz. IV Zoledronate         6 Partially                                                                                       
  1 Pz. Multiple myeloma                                                                                                                                        
  Seth, et al.^[@r43]^ 2010      11                           61.3 years (mean)     5 Pz. Breast cancer; 2   6 Pz. IV Zoledronate;                              11 Partially
  Pz. Prostate cancer;           2 Pz. OS Alendronate;                                                                                                          
  2 Pz Multiple myeloma          2 Pz. OS Ibandronate;                                                                                                          
  2 Pz. Osteoporosis             1 Pz. IV Etidronate                                                                                                            

###### 

Studies retrieved from the review of the literature: analysis of type of surgery, type of graft used, cumulative survival rate of the grafts and years of follow-up

  **Reference**                    **Number of patients**   **Type of study**   **Type of surgery**                     **Type of technique**                                                            **Cumulative survive rate of the grafts (CSR)**   **Years of follow-up**
  -------------------------------- ------------------------ ------------------- --------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------- -----------------------------
  Engroff and Kim^[@r12]^ \>2007   2                        Case series         Partial resection                       Vascularized fibula free flap                                                    100%                                              12 months
  Ferrari, et al.^[@r15]^ 2008     1                        Case report         Total resection                         Vascularized fibula free flap                                                    100%                                              12 months
  Mucke, et al.^[@r28]^ 2009       1                        Case report         Partial resection                       Vascularized fibula osteocutaneous free flap                                     100%                                              12 months
  Nocini, et al.^[@r29]^ 2009      7                        Case series         Partial resection and Total resection   Vascularized fibula free flap and Vascularized fibula osteocutaneous free flap   100%                                              Range: 6 to 34 months
  Seth, et al.^[@r43]^ 2010        11                       Case series         Partial resection                       Vascularized fibula osteocutaneous free flap                                     100%                                              Range: 2 weeks to 31 months

###### 

Studies retrieved from the review of the literature: analysis of type of reconstruction (fibula free flap - FFF and osteocutaneous fibula free flap - OFFF), particular procedures before surgery (hyperbaric oxygen therapy - HBO), postoperative wound complications and bisphosphonate-related osteonecrosis of jaws (BRONJ) recurrences

  **Reference**                  **Number of patients**   **Kind of graft used**                                         **Suggestions before surgery**                                    **Postoperative complication**                      **BRONJ recurrences**
  ------------------------------ ------------------------ -------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------
  Engroff and Kim^[@r12]^ 2007   2                        2 patients were reconstructed with an FFF                      ND                                                                1 postoperative neck hematoma, drained at bedside   1 patient developed contralateral mandible BRONJ, managed conservatively
  Ferrari, et al.^[@r15]^ 2008   1                        1 patient were reconstructed with FFF                          ND                                                                None                                                None
  Mucke, et al.^[@r28]^ 2009     1                        1 patient were reconstructed with OFFF                         ND                                                                None                                                None
  Nocini, et al.^[@r29]^ 2009    7                        6 patients were reconstructed with an FFF and 1 with an OFFF   B therapy was interrupted and 25 preoperative sessions of (HBO)   1 Rupture of a miniplate                            1 patient with short-term recurrence at resection margin, resolved
  Seth, et al.^[@r43]^ 2010      11                       11 patients were reconstructed with OFFF                       ND                                                                4 cases fistula and infection, all reselved         None

DISCUSSION
==========

BRONJ is a challenging complication to treat, in terms of both disease control and quality of life^[@r02],[@r46]^, and its treatment is still under discussion and unclear. Although recommendations for the management of this disease exist, they are dependent on a small group of patients. In addition, accordance about prevention or conservative treatment as the basis for \"at risk\" patients exist^[@r18],[@r23],[@r25]^. Medical treatments are routinely employed together with conservative surgery of the exposed necrotic bone^[@r22]^. However, the initial treatment should include improvement of oral hygiene and systemic antibiotics to prevent secondary infection and pain^[@r08],[@r14]^.

For the management of exposed necrotic bone, additional surgical debridement or sequestrectomy with primary mucosal closure seems to be effective in most cases. If there are recurrences at the conservative treatment, bone segment should be considered as it seems to be more successful than wound debridement alone^[@r29]^.

The reconstruction of subtotal mandibulectomy defects requires vascularized bone to promote healing and provide adequate soft-tissue support and oral competence^[@r11],[@r45]^. Engroff and Kim^[@r12]^ (2007), reported two cases of microvascular reconstruction of the mandible in BRONJ patients. Two lateral mandibular defects were successfully reconstructed with a fibula flap^[@r12]^.

Nocini, et al.^[@r30]^ (2009) in their case series have recently shown that a properly planned surgical resection has high curative potential in BRONJ patients. Mucke, et al.^[@r29]^ (2009) have shown that the effect of the transferred flap with also the vascularized iliac crest might represent a valuable technique. Despite the co-morbid conditions, the free bone-flap survival, the overall morbidity and the hospital stay, patients treated for osteonecrosis were comparable to that of patients whose mandibles are reconstructed because of osteoradionecrosis^[@r10],[@r17]^.

Patients with reasonable life expectancy with regard to their malignant disease should be considered for microvascular tissue transfer after aggressive resection of the affected region. The quality of life can be increased and a subset of patients with advanced disease can be cured of BRONJ. As already mentioned, the basic pathogenesis of this disease seems to be an avascular osteonecrosis, particularly involving the jaws. It seems therefore to be possible to treat patients with microvascular reconstruction of the jaws as the transferred bone receives direct blood supplementation from the anastomosed artery (superior thyroid or facial artery). The effect of the transferred flap with a new input of blood supply might be one of the reasons for the uneventful postoperative course in all patients. However, the cutaneous component of the flap provides additional soft tissue for reconstruction of resected fistulas and helps establish tension free wounds in the oral cavity. Seth, et al.^[@r44]^ (2010) have shown recently that vascularized bone graft reconstruction with osteocutaneous fibula free flap is feasible, offers a high success rate with only few postoperative wound complications selected patients with advanced cases of BRONJ.

According to literature^[@r12],[@r15],[@r29],[@r30],[@r44]^, radical surgical treatment has to be considered when:

\- BRONJ seems to involve a large area of the jaws;

\- the disease is not resolved by conservative therapy;

\- the donor site of the patient is well perfused;

\- the donor site of the patient is excluded by bone metastases.

However, the possibility of transferring cancer cells to the oral cavity during jawbone reconstruction with free bone flaps in patients with disseminated cancer or multiple myeloma has not been observed. Furthermore, fibula is rarely the site of metastatic bone disease or multiple myeloma^[@r20]^. Mandibular reconstruction using bone-containing microvascular flaps such as a fibula free flap is possible after a large resection and it gives also the opportunity of oral prosthetic rehabilitation using dental implants, as described by Ferrari, et al.^[@r15]^ (2008) in their clinical report.

CONCLUSIONS
===========

Osteonecrosis is a rare but significant complication of bisphosphonate therapy, and current literature supports only conservative defect reconstruction. These measures may not provide optimum reconstruction to achieve a well-vascularized healing environment, adequate oral function, and facial cosmetics. Microsurgical reconstruction of the jaws plays a critical role in improving the patient\'s quality of life. After an observation period of 12 months from microsurgical reconstruction of the jaws, high survival rates can be expected with few recurrences of osteonecrosis (9.09%). This, in turn, means that vascularized fibula flap technique has been well accepted by the clinician findings. Despite the limited number of patients found in the review of literature, this kind of treatment appears to be practicable in BRONJ-resected patients and does not seem to influence the natural course of the primary disease.
